Arvinas (ARVN) Q1 2025 earnings summary

Executive summary

• Achieved positive pivotal Phase 3 data for vepdegestrant (PROTAC degrader) in ER+/HER2- and ESR1 mutant metastatic breast cancer, supporting global regulatory filings and advancing toward commercial launch with Pfizer.

• Announced significant pipeline progress, including first-in-human data for ARV-102 (LRRK2 degrader) in neurodegeneration and preclinical/clinical updates for ARV-393 (BCL6 degrader) and ARV-806 (KRAS G12D degrader).

• Implemented a major restructuring, reducing workforce by about one-third and reprioritizing the portfolio to extend cash runway into the second half of 2028.

• Reported net income of $82.9 million for Q1 2025, a turnaround from a net loss of $69.4 million in Q1 2024, driven by collaboration revenue and cost management.

• Terminated the Bayer collaboration and amended the Yale license agreement, with future milestone and royalty obligations.

Financial highlights

• Q1 2025 revenue was $188.8 million, up from $25.3 million in Q1 2024, mainly due to changes in the vepdegestrant collaboration with Pfizer.

• Cash, cash equivalents, and marketable securities totaled $954.3 million as of March 31, 2025, down from $1.04 billion at year-end 2024.

• GAAP R&D expenses were $90.8 million (up $6.5 million YoY); non-GAAP R&D expenses were $79.3 million (up $7.4 million YoY).

• GAAP G&A expenses were $26.6 million (up $2.3 million YoY); non-GAAP G&A expenses were $23.1 million (up $5.1 million YoY).

• Net cash used in operating activities was $88.9 million, a decrease from $97.5 million in Q1 2024.

Outlook and guidance

• Cash runway projected to fund operations into the second half of 2028, supporting pipeline advancement and commercial readiness.

• Regulatory filing for vepdegestrant in ESR1 mutant metastatic breast cancer planned in the coming months, with NDA submission to the FDA in 2H 2025.

• Key data readouts expected in 2025 for ARV-102 (Parkinson’s disease), ARV-393 (hematology), and ARV-806 (KRAS G12D degrader in solid tumors), with ARV-806 Phase 1 trial to begin in H2 2025.